For adult patients with moderate to severe HS,

Redefine treatment with the FIRST and ONLY FDA-approved IL-17A antagonist1
Redefine treatment with the FIRST and ONLY FDA-approved IL-17A antagonist1
Across 2 clinical trials, the percentages of patients on COSENTYX® experiencing ≥50% reduction in the number of inflammatory nodules and abscesses, with no increase in the number of abscesses and/or in the number of draining tunnels, at Week 16 were Q4W: 41.3% and 42.5%; Q2W: 44.5% and 38.3% vs placebo: 29.4% and 26.1%, respectively.1
Data presented are the results of an FDA-requested analysis of the SUNSHINE and SUNRISE trials.
HiSCR50 is defined as at least a 50% decrease in abscess and inflammatory nodule (AN) count with no increase in the number of abscesses and/or in the number of draining fistulae compared with baseline.2
*If a patient does not adequately respond, consider increasing the dosage to 300 mg every 2 weeks.1
Observed results at Year 1
Improvement in inflammatory nodules and abscesses5
71% of patients had an observed ≥50% reduction (AN50) in the count of abscesses and nodules† at Year 1 in the Q4W arm (n=255)
71% of patients had an observed ≥50% reduction (AN50) in the count of abscesses and nodules† at Year 1 in the Q2W arm (n=254)
AN50 at 52 weeks were as observed prespecified exploratory end points. No clinical or statistical conclusions can be drawn.
Data shown are Q4W and Q2W, pooled from the SUNSHINE and SUNRISE trials.
†At Week 16, patients in the placebo group were randomized to either COSENTYX 300 mg Q2W or Q4W.
Patients with no new tunnel formation
83% of patients formed no new draining tunnels at Year 1 in the Q4W arm (n=218 with ≥1 draining fistula on COSENTYX 300 mg Q4W)7
81% of patients formed no new draining tunnels at Year 1 in the Q2W arm (n=239 with ≥1 draining tunnel Q2W 300 mg)7
Tunnels were as observed prespecified exploratory end points. No clinical or statistical conclusions can be drawn. Data shown are Q4W pooled data and Q2W pooled data from the SUNSHINE and SUNRISE trials.
Tunnels, also called fistulae or sinus tracts, are defined as raised, tender, and fluctuating longitudinal tunnels of variable length and depth, with communications to skin surface, with or without purulent discharge.2
“When draining, I have to wear all black to cover up any leaking through bandages. I used to travel a lot and was terrified I would leak onto the car seats or in meetings.”8
– Quote from a real patient with HS
Patients with zero flares
78% of patients had zero flares at Year 1 in the Q4W arm (n=127)2
80% of patients had zero flares at Year 1 in the Q2W arm (n=117)2
‡Q4W: Data presented are from the SUNRISE trial; the same results were not seen in SUNSHINE. Q2W: Data presented are from the SUNSHINE trial; the same results were not seen in SUNRISE. Flares were as observed prespecified exploratory end points at 52 weeks. No clinical or statistical conclusions can be drawn.
Flares were defined as a 25% or greater increase in abscess and inflammatory nodule count with a minimum increase of 2 abscesses and inflammatory nodules compared with baseline.2
"I’ve had flares under my armpits that were so massive that the vibrations of my footsteps would shoot up my body and cause too much pain to walk or bend over."10
– Quote from a real patient with HS
Patients with reduced skin pain
70% of those who started with moderate to severe skin pain had mild or no pain at Year 1 in the Q4W arm12
65% of those who started with moderate to severe skin pain had mild or no pain at Year 1 in the Q2W arm12
Skin pain was as observed prespecified exploratory end point. No clinical or statistical conclusions can be drawn. Data shown are Q4W pooled data and Q2W pooled data from the from SUNSHINE and SUNRISE trials.
§Based on VAS.
Provide patients hope for better days ahead2,14,15
At Week 16,
~3x improvement in DLQI across both trials vs placebo, with results maintained at Year 1
Components of DLQI include:
Feelings of embarrassment or self-consciousness
Daily activities, like shopping or caring for their home
Leisure activities, including socializing or playing a sport
Working or studying
Personal relationships with partners, close friends, or family
DLQI was 1 exploratory end point and was measured using multiple domains; each listed item was not evaluated separately. No clinical or statistical conclusions can be drawn. Data shown are from both Q4W and Q2W in both trials.2
DLQI includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school.16